Navigation Links
Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
Date:8/27/2008

fort and convenience.

Alexza has five product candidates in active clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed enrollment of its first Phase 3 clinical trial. A second Phase 3 clinical trial was initiated in July 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing and AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches is in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
2. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
3. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
4. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
5. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
6. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
9. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
10. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
11. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Metabolomics Market 2014-2018" report to ... Metabolomics or Metabonomics is the ... has become a new experimental technique that is ... environmental sciences. Metabolites are small molecules that are ...
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Sept. 7 The Plasma Protein Therapeutics Association (PPTA) ... (CMS) finalize its Proposed Rule regarding reimbursement to better ... outpatient setting. Specifically, for CY 2011, ... payable non-pass-through drugs and biologicals, which include most plasma ...
... Md., Sept. 3 The Maryland Stem Cell Research ... Cell Research Symposium in partnership with the National Institutes ... and Technology (NIST) on Wednesday, Sept. 22, 2010. The ... Life Science Research," will be held at the NIST ...
Cached Biology Technology:Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 2Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 3Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 4Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 5Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 6Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 7PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 2PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 3Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 2Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 3
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... rainfall are affecting the survival of elephants working in ... of death in calves aged up to five, new ... With climate change models predicting higher temperatures and ... already endangered Asian elephants. The researchers matched monthly ...
... TN Since the mid-nineteenth century, maps have helped ... yellow fever. Yet today,s global mapping of infectious diseases ... the control of potential outbreaks, according to a new ... known to humans., Of the 355 infectious diseases assessed ...
... mental health leads to unhealthy behaviors in low-income adults ... new study by Dr. Jennifer Walsh and colleagues from ... Miriam Hospital in the US. In this study, stress ... binge drinking, illegal drug use, unprotected sex and unhealthy ...
Cached Biology News:Low rainfall and extreme temperatures double risk of baby elephant deaths 2Avoiding a cartography catastrophe 2Poor mental health leads to unhealthy behaviors among low-income adults 2
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Human VEGF-D Biotinylated MAb (Clone 78923)...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Biology Products: